Literature DB >> 6746860

Necrotic changes in prolactinomas after long term administration of bromocriptine.

M Gen, T Uozumi, M Ohta, A Ito, H Kajiwara, S Mori.   

Abstract

Six prolactinoma patients were studied endocrinologically and their tumors were examined histologically after long term bromocriptine therapy. In patient 1 with a large prolactinoma, a marked reduction in size and a remarkable decrease in elevated serum PRL levels occurred after bromocriptine treatment for 8 months. The histological findings consisted of two components, i.e. shrunken island-like cell nests and acellular spaces. Some degenerative and necrotic tumor cells, hyaline substance, and fibrosis were observed with light and electron microscopy in these acellular spaces. Island-like cell nests consisted of atrophic cells having disproportionally scanty cytoplasm. The same histological findings were observed in four other patients. However, in another patient whose tumor decreased in size only slightly during bromocriptine therapy, the specimen had few acellular spaces. Thus, long term bromocriptine treatment of patients with prolactinomas may result in necrosis of some adenoma cells in some patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6746860     DOI: 10.1210/jcem-59-3-463

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Effect of dopaminergic drug treatment on surgical findings in prolactinomas.

Authors:  Maria Menucci; Alfredo Quiñones-Hinojosa; Peter Burger; Roberto Salvatori
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

2.  Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline.

Authors:  Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 3.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

4.  Microprolactinomas: why requiem for surgery?

Authors:  A Liuzzi; G Oppizzi
Journal:  J Endocrinol Invest       Date:  1996-03       Impact factor: 4.256

5.  Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine.

Authors:  I Halperin; M D Rodriguez; C Cardenal; R Casamitjana; M J Martinez Osaba; V Lienas; E Vilardell
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

6.  The future role of neurosurgery in medicine.

Authors:  W Luyendijk
Journal:  Neurosurg Rev       Date:  1986       Impact factor: 3.042

Review 7.  Medical treatment of pituitary adenomas: effects on tumor growth.

Authors:  A Liuzzi; P G Chiodini; D Dallabonzana; G Oppizzi; G G Verde
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

8.  Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients.

Authors:  M Muratori; M Arosio; G Gambino; C Romano; O Biella; G Faglia
Journal:  J Endocrinol Invest       Date:  1997-10       Impact factor: 4.256

9.  Topical effect of bromocriptine on rat-transplanted human prolactinomas.

Authors:  B Açikgöz; T Ozgen; O E Ozcan; S Ruacan; T Erbengi; M Sumnu
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

10.  Morphologic effects of bromocriptine on spontaneously occurring pituitary prolactin-cell hyperplasia in old Long-Evans rats.

Authors:  D J McComb; P Hellmann; M O Thorner; D Scott; W S Evans; K Kovacs
Journal:  Am J Pathol       Date:  1986-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.